AR and prostate carcinoma: Numerous studies have sought to characterise the molecular mechanisms underlying how prostate cancer becomes resistant to enzalutamide therapy, with AR amplification, AR variants, altered expression of AR co-regulators, upregulation of glucocorticoid receptor (GR), and metabolic alterations believed to play a role [95,96].